Community herbal monograph on
Valeriana officinalis
L.,
radix and
Humulus lupulus
L., flos
To be specified for the individual finished product.
Well-established use
Traditional use
With regard to the marketing authorisation
application of Article 10a of Directive 2001/83/EC
as amended
With regard to the registration application of
Article 16d(1) of Directive 2001/83/EC as
amended
Fixed combinations of
Valeriana officinalis
L.,
radix (valerian root) and
Humulus lupulus
L., flos
(hop strobiles)
Fixed combinations of
Valeriana officinalis
L.,
radix (valerian root) and
Humulus lupulus
L., flos
(hop strobiles)
i) Herbal substances
Not applicable
i) Herbal substances
Not applicable
ii) Herbal preparations used in fixed combinations
of
a) Dry extracts of valerian root (DER 4-8:1,
methanol 45-51% m/m) and hop strobiles
(DER 3-10:1, methanol 40-51% m/m)
ii) Herbal preparations used in fixed combinations
of
- Liquid extract (DER 1:6.3) from a mixture of
valerian root-hop strobiles (1:1), extraction
solvent ethanol 40% v/v
- Liquid extract from a mixture (1:1) of valerian
root tincture (DER 1:10), extraction solvent
ethanol 53% m/m and hop strobiles liquid
extract (DER 1:2.2), extraction solvent ethanol
53% m/m
b) Dry extracts of valerian root (DER 4-7:1,
ethanol 70% v/v) and hop strobiles (DER 4-
8:1, methanol 40% v/v)
- Dry extracts
a) Dry extracts of valerian root (DER 4-6:1),
extraction solvent water and hop strobiles (DER
3-6:1), extraction solvent water
b) Dry extracts of valerian root (DER 5-7:1),
extraction solvent methanol 45% m/m and hop
strobiles (DER 5-7:1), extraction solvent water
c) Dry extracts of valerian root (DER 4-5:1),
extraction solvent ethanol 60% v/v and hop
strobiles (DER 5-9:1), extraction solvent water
2 The material complies with the Ph. Eur. monograph (ref.: 01/2008:0453 and 01/2005:1222).
3 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
quality guidance.
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 4/8
d) Dry extracts of valerian root (DER 4-7:1),
extraction solvent methanol 45% v/v and hop
strobiles (DER 4-8:1), extraction solvent
ethanol 40% v/v
e) Dry extracts of valerian root (DER 3-7:1),
extraction solvent ethanol 70% v/v and hop
strobiles (DER 4-8:1), extraction solvent
ethanol 40% v/v
f) Dry extracts of valerian root (DER 6-7:1),
extraction solvent ethanol 70% v/v and hop
strobiles (DER 11-14:1), extraction solvent
ethanol 96% v/v
g) Dry extracts of valerian root (DER 5-8:1),
extraction solvent ethanol 85% v/v and hop
strobiles (DER 9-11:1), extraction solvent
ethanol 90% v/v
Well-established use
Traditional use
Herbal preparation in solid dosage forms for oral
use.
Herbal preparation in solid or liquid dosage forms
for oral use.
The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.
The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.
4.1.
Therapeutic indications
Well-established use
Traditional use
Indication 1)
Indication 1)
Herbal medicinal product for the relief of sleep
disorders.
Traditional herbal medicinal product for relief of
mild symptoms of mental stress.
Indication 2)
Traditional herbal medicinal product used to aid
sleep.
The product is a traditional herbal medicinal
product for use in specified indications exclusively
based on long-standing use.
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 5/8
4.2.
Posology and method of administration
Well-established use
Traditional use
Posology
Posology
Adolescents over 12 years of age, adults, elderly
Adolescents over 12 years of age, adults, elderly
Single dose
Liquid extracts:
Herbal preparation a): Fixed combinations of 187
mg/28 mg - 500 mg/65 mg dry extracts of
valerian root and hop strobiles, respectively
- Liquid extract (DER 1:6.3): single dose 20 ml
- Liquid extract (DER 1:1): 40 or 75 drops in a
half glass of water
1-2 doses half to one hour before bedtime, not
exceeding 500 mg of valerian extract.
Dry extracts:
a) Fixed combinations of 80 mg/20 mg or 160
mg/40 mg dry extracts of valerian root and hop
strobiles, respectively
Daily dosage: 3 x 3 doses or 3 x 2 doses for
indication 1 and 3 x 1 or 2 x 1 doses 1 hour
before bedtime for indication 2
Herbal preparation b): Fixed combination of 200
mg/45-mg – 350 mg/70 mg of dry extracts of
valerian root and hop strobiles, respectively
1-2 doses half to one hour before bedtime, not
exceeding 500 mg of valerian extract.
The use in children below the age of 12 years is
not recommended (see 4.4. ‘Special warning and
precautions for use’).
b) Fixed combination of 187 mg/45 mg dry
extracts of valerian root and hop strobiles,
respectively
Daily dosage: up to 3 x 1 doses for indication 1
and 1 dose 1 hour before bedtime for indication
2
Duration of use
Because of its gradual onset of efficacy fixed
combinations of valerian root and hops are not
suitable for acute interventional treatment of mild
nervous tension or sleep disorders. To achieve an
optimal treatment effect, the continued use over 4
weeks is recommended.
c) Fixed combinations of 100 mg/30 mg of dry
extracts of valerian root and hop strobiles,
respectively
Daily dosage: 2-3 doses for indication 1 and 2
doses 1 hour before bedtime for indication 2
If symptoms persist or worsen after 4 weeks of
continued use, a doctor should be consulted.
d) Fixed combinations of 125 mg/25 mg of dry
extracts of valerian root and hop strobiles,
respectively
Daily dosage: up to 3 x 2 doses for indication 1
and 2 doses 1 hour before bedtime for
indication 2
Method of administration
Oral use.
e1) Fixed combinations of 100 mg/24 mg – 32 mg
dry extracts of valerian root and hop strobiles,
respectively
Daily dosage: 3 x 2 doses for indication 1 and 2
doses 1 hour before bedtime for indication 2
e2) Fixed combinations of 68 mg/16 mg of dry
extracts of valerian root and hop strobiles,
respectively
Daily dosage: 3 x 3 doses for indication 1 and 3
doses 1 hour before bedtime for indication 2
f) Fixed combinations of 225 mg/30 mg dry
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 6/8
extracts of valerian root and hop strobiles,
respectively
Daily dosage: 3x1 doses for indication 1 and 1-
2 doses 1 hour before bedtime for indication 2
g) Fixed combinations of 77 mg/18.8 mg of dry
extracts of valerian root and hop strobiles,
respectively
Daily dosage: 3 x 2 doses for indication 1 and 2
doses 1 hour before bedtime for indication 2
The use in children below the age of 12 years is
not recommended (see 4.4. ‘Special warning and
precautions for use’).
Duration of use
If the symptoms persist longer than 4 weeks of
continued use of the medicinal product, a doctor
or a qualified health care practitioner should be
consulted.
Method of administration
Oral use.
4.3.
Contraindications
Well-established use
Traditional use
Hypersensitivity to the active substances.
Hypersensitivity to the active substances.
4.4.
Special warnings and precautions for use
Well-established use
Traditional use
The use of these fixed combinations is not
recommended in children below the age of 12
years, due to lack of adequate data.
The use of these fixed combinations is not
recommended in children below the age of 12
years, due to lack of adequate data.
For extracts containing ethanol, the appropriate
labelling for ethanol, taken from the “Guideline on
excipients in the label and package leaflet of
medicinal products for human use” must be
included.
4.5.
Interactions with other medicinal products and other forms of
interaction
Well-established use
Traditional use
Only limited data on pharmacological interactions
with other medicinal products are available.
Only limited data on pharmacological interactions
with other medicinal products are available.
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 7/8
Clinically relevant interaction with drugs
metabolised by the CYP 2D6, CYP 3A4/5, CYP 1A2
or CYP 2E1 pathway has not been observed.
Combination with synthetic sedatives requires
medical diagnosis and supervision.
Clinically relevant interaction with drugs
metabolised by the CYP 2D6, CYP 3A4/5, CYP 1A2
or CYP 2E1 pathways has not been observed.
Combination with synthetic sedatives is not
recommended.
4.6.
Pregnancy and lactation
Well-established use
Traditional use
Safety during pregnancy and lactation has not
been established.
As a precautionary measure, because of lack of
data, use during pregnancy and lactation is not
recommended.
Safety during pregnancy and lactation has not
been established.
As a precautionary measure, because of lack of
data, use during pregnancy and lactation is not
recommended.
4.7.
Effects on ability to drive and use machines
Well-established use
Traditional use
May impair ability to drive and use machines.
Affected patients should not drive or operate
machinery.
May impair ability to drive and use machines.
Affected patients should not drive or operate
machinery.
4.8.
Undesirable effects
Well-established use
Traditional use
Gastrointestinal symptoms (e.g. nausea,
abdominal cramps) may occur after ingestion of
valerian root preparations. The frequency is not
known.
Gastrointestinal symptoms (e.g. nausea,
abdominal cramps) may occur after ingestion of
valerian root preparations. The frequency is not
known.
If other adverse reactions not mentioned above
occur, a doctor or a pharmacist should be
consulted.
If other adverse reactions not mentioned above
occur, a doctor or a qualified health care
practitioner should be consulted.
Well-established use
Traditional use
Valerian root at a dose of approximately 20 g
caused benign symptoms (fatigue, abdominal
cramp, chest tightness, lightheadedness, hand
tremor and mydriasis), which disappeared within
24 hours. If symptoms arise, treatment should be
supportive.
Valerian root at a dose of approximately 20 g
caused benign symptoms (fatigue, abdominal
cramp, chest tightness, lightheadedness, hand
tremor and mydriasis), which disappeared within
24 hours. If symptoms arise, treatment should be
supportive.
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 8/8
5.1.
Pharmacodynamic properties
Well-established use
Traditional use
Pharmacotherapeutic group: Hypnotics and
sedatives.
Not required as per Article 16c (1)(a)(iii) of
Directive 2001/83/EC as amended.
ATC Code: N05CM09.
The sedative effects of preparations of valerian
root and hop strobiles have been long recognised
empirically and have been confirmed for valerian
root preparations in preclinical tests and
controlled clinical studies. So far no clinical
studies have been conducted with hop extracts
alone as active drug for insomnia, but at least
four randomized, placebo- or reference-controlled
prospective clinical studies have been carried out
with fixed combinations of dry extracts prepared
from valerian root and hop strobiles with
methanol 45% (m/m).
Orally administered fixed combinations of these
extracts in the recommended dosage have been
shown to improve sleep latency and sleep quality.
These effects cannot be attributed with certainty
to any known constituents. Several mechanisms
of action possibly contributing to the clinical effect
have been identified for diverse constituents of
valerian root (sesquiterpenoids, lignans,
flavonoids) and include interactions with the
GABA-system, agonism at the A-1 adenosine
receptor and binding to the 5-HT1A receptor. Also
several mechanisms of action have been identified
for diverse constituents of hop strobiles (bitter
acids, flavonoids) and include interactions with
the GABA-system, agonism at the melatonin
receptors (ML1 and ML2) and binding to serotonin
receptor subtypes (5-HT
4e
, 5-HT
6
and 5-HT
7
).
Whether hop strobile extract acts either as a mild
sedative independently or as a synergist for
valerian root extract, is not yet known.
5.2.
Pharmacokinetic properties
Well-established use
Traditional use
No data available.
Not required as per Article 16c (1)(a)(iii) of
Directive 2001/83/EC as amended.
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 9/8
5.3.
Preclinical safety data
Well-established use
Traditional use
Extracts with ethanol and the essential oil of
valerian root have shown low toxicity in solvents
during acute tests and from repeated dose toxicity
over periods of 4-8 weeks.
Tests on reproductive toxicity, genotoxicity and
carcinogenocity of valerian root preparations have
not been performed.
Tests on genotoxicity of water/ethanolic extracts
of hop strobiles were negative.
Tests on genotoxicity were not performed for
water extracts of hops.
Tests on reproductive toxicity and carcinogenicity
of hop preparations have not been performed.
Not required as per Article 16c(1)(a)(iii) of
Directive 2001/83/EC as amended, unless
necessary for the safe use of the product.
Extracts with ethanol and the essential oil of
valerian root have shown low toxicity in rodents
during acute tests and from repeated dose toxicity
over periods of 4-8 weeks.
Tests on reproductive toxicity, genotoxicity and
carcinogenocity of valerian root preparations have
not been performed.
Tests on genotoxicity of water/ethanolic extracts
of hop strobiles were negative.
Tests on genotoxicity were not performed for
water extracts of hops.
Tests on reproductive toxicity and carcinogenicity
of hop preparations have not been performed.
Well-established use
Traditional use
Not applicable.
Not applicable.
6 June 2011
Community herbal monograph on
Valeriana officinalis
L., radix and
Humulus lupulus
L., flos
EMA/HMPC/585558/2007
Page 10/8
Assessment Report
ASSESSMENT REPORT
FOR HERBAL SUBSTANCE(S), HERBAL PREPARATION(S) OR COMBINATIONS
THEREOF WITH WELL-ESTABLISHED USE AND TRADITIONAL USE
BASED ON ARTICLE 10A OF DIRECTIVE 2001/83/EC AS AMENDED
(WELL-ESTABLISHED USE)
BASED ON ARTICLE 16D(1) AND ARTICLE 16F AND 16H OF DIRECTIVE 2001/83/EC AS
AMENDED
(TRADITIONAL USE)
Herbal substance(s) (binomial scientific name of
the plant, including plant part)
Fixed combinations of
Valeriana officinalis
L.,
radix (valerian root) and
Humulus lupulus
L., flos
(hop strobiles)
Herbal preparation(s)
Dry, liquid and soft extracts
Pharmaceutical forms
Oral administration
Rapporteur
Prof. Dr. A. J. Vlietinck
EMEA 2009
2/40
I.
MA: Marketing Authorisation;
TRAD: Traditional Use Registration;
Other TRAD: Other national Traditional systems of registration;
Other: If known, it should be specified or otherwise add ’Not Known’
Member State
Regulatory Status
Austria
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Belgium
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Bulgaria
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Cyprus
MA
TRAD
Other TRAD
Other Specify:
Czech Republic
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Denmark
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Estonia
MA
TRAD
Other TRAD
Other Specify:
Food suppl.
Finland
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
France
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Germany
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Greece
MA
TRAD
Other TRAD
Other Specify:
Hungary
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Iceland
MA
TRAD
Other TRAD
Other Specify:
None
Ireland
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Italy
MA
TRAD
Other TRAD
Other Specify: Only food
supplements
Latvia
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Liechtenstein
MA
TRAD
Other TRAD
Other Specify:
Lithuania
MA
TRAD
Other TRAD
Other Specify:
Luxemburg
MA
TRAD
Other TRAD
Other Specify:
Malta
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
The Netherlands
MA
TRAD
Other TRAD
Other Specify:
Norway
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Poland
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Portugal
MA
TRAD
Other TRAD
Other Specify:
Romania
MA
TRAD
Other TRAD
Other Specify:
Slovak Republic
MA
TRAD
Other TRAD
Other Specify:
None
Slovenia
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
Spain
MA
TRAD
Other TRAD
Other Specify:
None
Sweden
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
United Kingdom
MA
TRAD
Other TRAD
Other Specify:
+ Other combi
1
This regulatory overview is not legally binding and does not necessarily reflect the legal status of the products
in the MSs concerned.
2
Not mandatory field
3/40
EMEA 2009
II.
ASSESSMENT REPORT
II.1
INTRODUCTION
II.1.1.
Herbal preparations
AUSTRIA
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 Aponova Schlaf- und Beruhigungsdragees:
1 coated tablet: 64 mg Valerian extract (3:7:1,
ethanol), 40 mg hops extract (6.6-8.4:1, ethanol),
1996
coated tablet
Adults 3 x daily 2-4 tablets, in case to aid
sleep 3-5 tablets in the evening
restlessness, anxiety, mild forms
of sleep disorders, stage-fright,
nervous heart disorders
2
Ardeysedon Dragees: 1 coated tablet: 100 mg
Valerian extract (4-7:1, ethanol 70% v/v), 24 mg
hops extract (4-8:1, ethanol 40% v/v)
2003
coated tablet
Adults, adolescents and children > 10
years: sleep disorders 2 tablets in the
evening; restlessness: max. 3 x daily 2
tablets
restlessness, mild forms of sleep
disorders
3
Ardeysedon forte-Dragees: 1 coated tablet: 200
mg Valerian extract (4-7:1, ethanol 70% v/v), 68
mg hops extract (4-8:1, ethanol 40% v/v)
2005
coated tablet
Adults, adolescents and children > 10
years: sleep disorders1 tablets in the
evening; restlessness: max. 3 x daily 1
tablet
restlessness, mild forms of sleep
disorders
4
Hova Filmtabletten: 1 coated tablet contains:
200.2 mg Valerian extract (4-7:1, ethanol 70%
v/v), 45.5 mg hops extract (4-8:1, methanol 40%
v/v)
1993
film coated
tablet
restlessness: 1-3 times daily 1 tablet;
nervous sleep disorders: 2 tablets in the
evening (children 6-12 years: 1 tablet)
restlessness, nervous sleep
disorders
TU
No Marketing status
Year
Pharm form Posology
Indications
1 Bakanasan Baldrian Perlen + Hopfen: 55 mg
Valerian extract (3:1, water), 10 mg hops extract
(3:1, water)
1991
coated tablet Sleep disorders 3-5 tablets in the evening;
restlessness: 3 x daily 2 tablets
restlessness, mild forms of sleep
disorders, nervousness
2
Bakanasan Baldrian-Hopfen-Dragees: 68 mg
Valerian extract (3-6:1, ethanol), 16 mg hops
extract (4-8:1, water)
2002
coated tablet Sleep disorders 3 tablets in the evening;
restlessness: 3 x daily 2 tablets
to aid sleep, nervousness,
restlessness
3
Baldrian Dispert comp. Dragees: 100 mg Valerian
extract (ethanol), 24 mg hops extract (ethanol)
1996
coated tablet 2 tablets in the evening
nervous sleep disorders
4/40
EMEA 2009
4
Biogelat Schlafkapseln: 220 mg Valerian extract
(6:1, stand. to min. 5% sesquiterpene acids,
ethanol), 50 mg hops extract (7.5:1, stand. to min.
0.4% flavonoids, ethanol)
1996
capsule
in the evening 1-2 capsules
nervous sleep disorders
5
Einschlafkapseln Twardy: 100 mg Valerian
extract (3-6:1, ethanol), 30 mg hops extract (4-
8:1, ethanol)
1993
capsule
3 capsules (children 2 capsules) in the
evening
nervous sleep disorders,
nervousness
6
Klosterfrau Beruhigungskapseln: 250 mg Valerian
extract (), 65 mg hops extract ()
1995
capsule
2-4 times daily 1 capsule, 1 capsule in the
evening
restlessness, nervous sleep
disorders
7
Luvased Dragees: 75 mg Valerian extract
(methanol), 70 mg hops extract (methanol
1994
coated tablet adults: 1-2 tablets several times; when
given in the evenening 2-4 tablets; school
children 3 x daily 1 tablet
restlessness, mild forms of sleep
disorders, nervousness
8
Sanhelios Einschlaf Kapseln: 100 mg Valerian
extract (), 25 mg hops extract ()
1993
capsule
3 x daily 1-2 capsules; or in the evening
2-3 capsules
for sedation, nervous sleep
disorders
9
Wellness Baldrian Hopfen forte Kapseln: 220 mg
Valerian extract (6:1, stand. to min. 5%
sesquiterpene acids, ethanol), 50 mg hops extract
(7.5:1, stand. to min. 0.4% flavonoids, ethanol)
1998
capsule
up to 3 x daily 1 capsule, in case of sleep
disorders 1-2 capsules in the evening
restlessness, nervous sleep
disorders
10
Wellness Baldrian Hopfen Dragees: 60g Valerian
extract (4:1), 30g hops extract (5:1)
1990
coated tablet
1-3 x daily 1 tablet; in case of sleep
disorders 2-3 tablets in the evening
restlessness, nervous sleep
disorders
The product Hova contains:
1 coated tablet contains
45.5 mg dry extract of hop strobiles, DER 4-8:1, extraction solvent methanol 40% (v/v)
200.2 mg dry extract of valerian root, DER 4-7:1, extraction solvent ethanol 70% (v/v)
Posology:
As an aid to sleep: adults and adolescents 2 coated tablets in the evening, children from 6-12 years of age (when recommended by a doctor) 1 coated tablet.
Restlessness, nervosity: adults and adolescents 1-3 x daily 1 coated tablet, children from 6-12 years of age (when recommended by a doctor) 1-2 x daily 1 coated
tablet.
Previous documents state a DER of the valerian extract of 5:1 and of the hops extract 5,5:1. It is not clear for me whether the company changed the specification of
the extracts recently or they made a correction to the actual conditions in the manufacturing process.
EMEA 2009
5/40
BELGIUM
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 Peroben tablets
1 tablet contains 250mg valerian root dry
extract(4.5:1,
methanol 50%, v/v) and 65 mg hops dry extract
(4:1, methanol 50% v/v)
2000
coated
Adults, adolescents>12 years, sleep
disorders;1-2 tablets in the evening,
restlessness ;1-2 tablets 3x daily
Restlessness, nervous sleep disorders
TU
No Marketing status
Year
Pharm form Posology
Indications
BULGARIA
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 Valerianae radix extractum siccum (4-6:1); Lupuli
strobuli extractum siccum (5-7:1); extraction
solvent: methanol 45%
2003
film coated
tablets
Adults take two tablets with some liquid
one hour before going to bed. Children 6
years and older get half the dosage, i.e. 1
tablet.
Difficulties in falling asleep and
sleeping through the night as well
as uneasy sleep
TU
No Marketing status
Year
Pharm form Posology
Indications
EMEA 2009
6/40
CZECH REPUBLIC
WEU
No Marketing status
Year
Pharm form Posology
Indications
TU
No Marketing status
Year
Pharm form Posology
Indications
1
Dry extract from Valerian root, DER 4-7 :1,
extraction solvent ethanol 70% (V/V)
- 200.2 mg/tbl
Dry extract from Hop strobiles, DER 4-8 : 1,
extraction solvent methanol 40% (V/V)
– 45.5 mg/tbl
1999
por tbl flm
for oral use
sleep disturbances:
adults - two coated tablets (corresponding
to 400.4 mg of Valerian extract and 91
mg of Hop extract) ½ hour before bedtime
children over 6 years and adolescents -
one coated tablets (corresponding to 200.2
mg of Valerian extract and 45.5 mg of
Hop extract) ½ hour before bedtime
therapy of sleep disorders due to
nervosity; restlessness, nervosity,
anxiety
restlessness, nervosity, anxiety:
one tablet (corresponding to 200.2 mg of
Valerian extract and 45.5 mg of Hop
extract) 3 times daily
2
Dry extractfrom Valerian root, DER 4-7 :1,
extraction solvent ethanol 70% (V/V) – 60 mg/tbl
Dry extract from Hop strobiles, DER 11-14 : 1,
extraction solvent ethanol 96% (V/V) – 60 mg/tbl
1993
por tbl flm
for oral use
adults 2 – 3 coated tablets (corresponding
to 120 – 180 mg of Valerian extract and
120 – 180 mg of Hop extract) 1 hour
before bedtime
children over 6 years 1 – 2 coated tablets
(corresponding to 60 -120 mg
of Valerian extract and 60 - 120 mg of
Hop extract) 1 hour before bed time
sleep disorders due to
restlessness, anxiety, excitement
and tension
EMEA 2009
7/40
DENMARK
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 Extract of Humulus lupulus (4:1) 50 mg
Extract of Radix valeriane (4:1) 50 mg
before
1992
Capsules
2-3 capsules before bedtime
Herbal medicinal product for
relief of restlessness and
difficulty of falling asleep
2 Extract of Humulus lupulus (5.5:1) 16 mg
Extract of Radix valeriane (4.5:1) 68 mg
2000 -
2003
Tablets
TU
No Marketing status
Year
Pharm form Posology
Indications
ESTONIA
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 BECALM TBL N30 , food supplement
2005
Tablet
Take one tablet twice a day
Anxiety, nervousness, stress.
2 ABO HOP - VALERIAN CAPSULES N60, food
supplement
2005
Capsule
Take two capsules 2-3 times a day or two
capsules before bedtime
Nervous sleeping disorders and
conditions of unrest
TU
No Marketing status
Year
Pharm form Posology
Indications
EMEA 2009
8/40
GERMANY
WEU
ES = extraction solvent
No Marketing status
Year
Pharm form Posology
Indications
1 dry extract from Valerianae radix (4-6:1), ES
water and dry extract from Lupuli flos (3-6:1), ES
water
1976
coated tablet 1 coated tablet contains 80 mg dry extract
from Valerianae radix and 20 mg dry
extract from Lupuli flos
Indication A
) Up to 3 x daily 3 coated
tablets
Indication B)
3 coated tablets 1/2 - 1 h
before bedtime. If necessary, additionally
3 coated tablets earlier in the evening.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
2 dry extract from Valerianae radix (6-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(11-14:1), ES ethanol 96% V/V
1976
coated tablet 1 coated tablet contains 225 mg dry
extract from Valerianae radix and
30 mg dry extract from Lupuli flos
Indication A
) 1-3 x daily 1 coated tablet
Indication B)
1-2 coated tablets 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
3 dry extract from Valerianae radix (4-6.7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4.3-7.7:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 100 mg dry
extract from Valerianae radix and 24 mg
dry extract from Lupuli flos
Indication B
) 2 coated tablets 1/2 - 1 h
before bedtime If necessary, additionally
2 coated tablets earlier in the evening
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
4 dry extract from Valerianae radix (5.5-7.4:1), ES
ethanol 85% V/V and dry extract from Lupuli flos
(9-11:1), ES ethanol 90% V/V
1976
coated tablet 1 coated tablet contains 77 mg dry extract
from Valerianae radix and 18.8 mg dry
extract from Lupuli flos
Indication A)
Up to 3 x daily 2 coated
tablets
Indication B)
2 coated tablets 1/2 - 1 h
before bedtime.
If necessary, additionally 2 coated tablets
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
EMEA 2009
9/40
earlier in the evening
asleep
5 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (7.7-9.5:1), ES methanol 45% m/m
1976
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and 14 mg
dry extract from Lupuli flos
Indication A
) 1-3 x daily 2 coated tablets
Indication B
) 2 coated tablets 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
6 dry extract from Valerianae radix (4-6:1), ES
water and dry extract from Lupuli flos (3-6:1), ES
water
1976
coated tablet 1 coated tablet contains 160 mg dry
extract from Valerianae radix and 40 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 2 coated
tablets
Indication B
) 2 coated tablets 1/2 - 1 h
before bedtime.
If necessary, additionally 2 coated tablets
earlier in the evening.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
7 dry extract from Valerianae radix (4-5:1), ES
methanol 50% V/V and dry extract from Lupuli
flos (3.4-4.2:1), ES methanol 50% V/V
1976
coated tablet 1 coated tablet contains 250 mg dry
extract from Valerianae radix and 65 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B
) 1 coated tablet 1/2 - 1 h
before bedtime.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
8 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1999
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and 68 mg
dry extract from Lupuli flos
Indication B
) 1 coated tablet 1/2 - 1 h
before bedtime
If necessary, additionally 1 coated tablet
earlier in the evening.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
EMEA 2009
10/40
9 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1998
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and 68 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B
) 1 coated tablet 1/2 - 1 h
before bedtime
If necessary, additionally 1 coated tablet
earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
10 dry extract from Valerianae radix (6-7.4:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(11-14:1), ES ethanol 96% V/V
1999
soft capsule
1 soft capsule contains 170 mg dry extract
from Valerianae radix and 25 mg dry
extract from Lupuli flos
Indication A
) Up to 3 x daily 1 soft
capsule
Indication B
) 1 soft capsule 1 h before
bedtime.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
11 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (7.7-9.5:1), ES methanol 45% m/m
1976
soft capsule
1 soft capsule contains 200 mg dry extract
from Valerianae radix and 35 mg dry
extract from Lupuli flos
Indication A
) Up to 3 x daily 1 soft
capsule
Indication B
) 1 soft capsule 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
12 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES methanol 40% V/V
1976
coated tablet 1 coated tablet contains 175 mg dry
extract from Valerianae radix and 35 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 2 coated
tablets
Indication B)
2 coated tablets 1/2 - 1 h
before bedtime.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
EMEA 2009
11/40
13 dry extract from Valerianae radix (5.3-6.6:1), ES
methanol 45% m/m and dry extract from Lupuli
flos (5.5-6.5:1), ES water
1976
coated tablet 1 coated tablet contains 187.5 mg dry
extract from Valerianae radix and 45 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B)
1 coated tablet 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
14 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (4-8:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 125 mg dry
extract from Valerianae radix and 25 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 2 coated
tablets
Indication B)
2 coated tablets 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
15 dry extract from Valerianae radix (3-6:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 68 mg dry extract
from Valerianae radix and 16 mg dry
extract from Lupuli flos
Indication A and B
) Up to 3 x daily 3
coated tablets
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
16 dry extract from Valerianae radix (4-5:1), ES
ethanol 60% V/V and dry extract from Lupuli flos
(5.88-6.6:1), ES water
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 30 mg dry
extract from Lupuli flos
Indication A
) 2- 3 x daily 2 soft capsules
Indication B
) 2 soft capsules approx. 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
EMEA 2009
12/40
17 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (4-8:1), ES methanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 25.02 mg dry
extract from Lupuli flos
Indication A
) 1- 3 x daily 2 soft capsules
Indication B
) 2 soft capsules ½ - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
18 dry extract from Valerianae radix (3-6:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 30 mg dry
extract from Lupuli flos
Indication B
) 2 soft capsules 1/2 - 1 h
before bedtime
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
19 dry extract from Valerianae radix (3-6:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 30 mg dry
extract from Lupuli flos
Indication B
) 2 soft capsules 1/2 - 1 h
before bedtime
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
20 dry extract from Valerianae radix (3-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 100 mg dry
extract from Valerianae radix and 24 mg
dry extract from Lupuli flos
Indication A)
Up to 3 x daily 2 coated
tablets
Indication B)
2 coated tablets 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
21 dry extract from Valerianae radix (5.3-6.6:1), ES
methanol 45% m/m and dry extract from Lupuli
flos (5.5-6.5:1), ES water
1976
coated tablet 1 coated tablet contains 187 mg dry
extract from Valerianae radix and 45 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B)
1 coated tablet 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
EMEA 2009
13/40
22 dry extract from Valerianae radix (5-8:1), ES
methanol 45% m/m and dry extract from Lupuli
flos (7-10:1), ES methanol 45% m/m
1976
film-coated
tablet
1 film-coated tablet contains 187 mg dry
extract from Valerianae radix and 41.88
mg dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 film-
coated tablet
Indication B)
1 film-coated tablet 1/2 - 1
h before bedtime
If necessary, additionally 1 film-coated
tablet earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
23 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (4-8:1), ES ethanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 25.02 mg dry
extract from Lupuli flos
Indication A
) 2-3 x daily 2 soft capsules
Indication B
) 2 soft capsules 1/2 h before
bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
24 dry extract from Valerianae radix (3-6:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and 30 mg dry
extract from Lupuli flos
Indication B
) 2 soft capsules 1/2 - 1 h
before bedtime
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
25 dry extract from Valerianae radix (5.3-6.6:1), ES
methanol 45% m/m and dry extract from Lupuli
flos (5.5-6.5:1), ES water
1976
coated tablet 1 coated tablet contains 187 mg dry
extract from Valerianae radix and 45 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B)
1 coated tablet 1/2 - 1 h
before bedtime
If necessary, additionally 1 coated tablet
earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
26 dry extract from Valerianae radix (4-6.7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4.3-7.7:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 100 mg dry
extract from Valerianae radix and 32 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 2 coated
tablets
Indication B
) 2 coated tablets 1/2 - 1 h
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
EMEA 2009
14/40
before bedtime
Herbal medicinal product for the
relief of difficulty in falling
asleep
27 dry extract from Valerianae radix (3-6:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1976
coated tablet 1 coated tablet contains 68 mg dry extract
from Valerianae radix and 16 mg dry
extract from Lupuli flos
Indication A
) Up to 3 x daily 3 coated
tablets
Indication B)
3 coated tablets 1/2 - 1 h
before bedtime
If necessary, additionally 2 x 3 coated
tablet earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
28 dry extract from Valerianae radix (5.3-6.6:1), ES
methanol 45% m/m and dry extract from Lupuli
flos (5.5-6.5:1), ES water
1976
coated tablet 1 coated tablet contains 187.5 mg dry
extract from Valerianae radix and
45 mg dry extract from Lupuli flos
Indication A
) 1 x daily 1 coated tablet
Indication B)
1 coated tablet 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
29 dry extract from Valerianae radix (4-7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (4-8:1), ES methanol 40% V/V
1976
soft capsule
1 soft capsule contains 100 mg dry extract
from Valerianae radix and
25.02 mg dry extract from Lupuli flos
Indication A
) 1- 3 x daily 2 soft capsules
Indication B
) 2 soft capsules ½ - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
30 dry extract from Valerianae radix (4-6.7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (7.7-9.5:1), ES methanol 45% m/m
1976
soft capsule
1 soft capsule contains 200 mg dry extract
from Valerianae radix and
35 mg dry extract from Lupuli flos
Indication A
) 2 x daily 1 soft capsule
Indication B
) 1 soft capsule 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
EMEA 2009
15/40
asleep
31 dry extract from Valerianae radix (4-6.7:1), ES
methanol 45% V/V and dry extract from Lupuli
flos (4.3-7.7:1), ES methanol 40% V/V
1976
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and
48 mg dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B)
1 coated tablet 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
32 dry extract from Valerianae radix (4-6:1), ES
water and dry extract from Lupuli flos (3-6:1), ES
water
1976
coated tablet 1 coated tablet contains
160 mg dry extract from Valerianae radix
and 40 mg dry extract from Lupuli flos
Indication A
) Up to 3 x daily 2 coated
tablets
Indication B
) 2 coated tablets 1/2 - 1 h
before bedtime.
If necessary, additionally 2 coated tablets
earlier in the evening.
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
33 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1996
coated tablet 1 coated tablet contains 100 mg dry
extract from Valerianae radix and
24 mg dry extract from Lupuli flos
Indication A)
Up to 3 x daily 2 coated
tablets
Indication B)
2 coated tablets 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
34 dry extract from Valerianae radix (4-5:1), ES
methanol 51.25% V/V and dry extract from
Lupuli flos (3.4-4.2:1), ES methanol 51.25% V/V
1993
soft capsule
1 soft capsule contains 250 mg dry extract
from Valerianae radix and
65 mg dry extract from Lupuli flos
Indication A
) Up to 2 x daily 1 soft
capsule
Indication B
) 1 soft capsule 1/2 - 1 h
before bedtime
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
EMEA 2009
16/40
35 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1998
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and 68 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B
) 1 coated tablet 1/2 - 1 h
before bedtime
If necessary, additionally 1 coated tablet
earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
36 dry extract from Valerianae radix (4-7:1), ES
ethanol 70% V/V and dry extract from Lupuli flos
(4-8:1), ES ethanol 40% V/V
1998
coated tablet 1 coated tablet contains 200 mg dry
extract from Valerianae radix and 68 mg
dry extract from Lupuli flos
Indication A
) Up to 3 x daily 1 coated
tablet
Indication B
) 1 coated tablet 1/2 - 1 h
before bedtime
If necessary, additionally 1 coated tablet
earlier in the evening
Indication A) "Unruhezustände"
Herbal medicinal product for the
relief of mild nervous tension.
Indication B) "nervös bedingte
Einschlafstörungen"
Herbal medicinal product for the
relief of difficulty in falling
asleep
TU
ES = extraction solvent
No Marketing status
Year
Pharm form Posology
Indications
1
dry extract from Valerianae radix (4-6.7:1), ES
ethanol 40% V/V and dry extract from Lupuli flos
(4.3-7.7:1), ES ethanol 40% V/V
1976
coated tablet
for oral use in adults and adolescents over
12 years
1 coated tablet contains
32 mg dry extract from Valerianae radix
and
9 mg dry extract from Lupuli flos
2-3 x daily 1 coated tablet
"Traditionell angewendet zur
Besserung des Befindens bei
nervlicher Belastung. Diese
Angabe beruht ausschließlich auf
Überlieferung und langjähriger
Erfahrung."
Traditional herbal medicinal
product for support of mental
relaxation. The product is a
traditional herbal medicinal
product for use in specified
indications exclusively based on
long-standing use
2
liquid extract (1:6.3) from a mixture of Valerianae
radix : Lupuli flos (1:1), ES ethanol 40% V/V
1976
oral liquid
for oral use in adults
3 x daily 20 ml containing 12% V/V
"Traditionell angewendet zur
Besserung des Befindens bei
EMEA 2009
17/40
extract
nervlicher Belastung. Diese
Angabe beruht ausschließlich auf
Überlieferung und langjähriger
Erfahrung."
Traditional herbal medicinal
product for support of mental
relaxation. The product is a
traditional herbal medicinal
product for use in specified
indications exclusively based on
long-standing use
3
soft extract (5-6.7:1) from a mixture of Valerianae
radix : Lupuli flos (5.7:1), ES methanol 40% V/V
1976
liquid bath
additive
for external use as bath additive in adults
and adolescents over 12 years
100 g (= 92.2 ml) bath additive contain
11.7 g soft extract
30 ml liquid bath additive / 120 l water
maximal 2 x weekly
bath duration 10-20 min
bath temperature 34-37ºC
"Traditionell angewendet zur
Besserung des Befindens bei
nervlicher Belastung. Diese
Angabe beruht ausschließlich auf
Überlieferung und langjähriger
Erfahrung."
Traditional herbal medicinal
product for support of mental
relaxation. The product is a
traditional herbal medicinal
product for use in specified
indications exclusively based on
long-standing use
Müller-Limmroth & Ehrenstein (1977)
For the publication the medicinal product “Seda-Kneipp” was used, as referred to in the article. At this time the product was composed as
following:
60 mg dry extract of Valeriana (4.5:1); methanol 40% (V/V)
100 mg dry extract from Hop (5:1); methanol 30% (V/V).
Later (1994) the composition was changed. It was now:
77 mg dry extract from Valerian (5.5-7.4:1); ethanol 85% (V/V) 18.8 mg dry extract from Hop (9-11:1); ethanol 90% (V/V).
EMEA 2009
18/40
HUNGARY
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 25mg Valeriaenae radix, dry extract ethanolic
70% (V/V), (4-7:1)
100mg Lupuli flos, dry extract methanolic 40%
(V/V), (4-8:1)
(Hovaletten dragées)
1996
film coated
tablet
Adults:
Sleeping disorders: 4-5 db film tablets
half an hour before going to bed.
Restlessness, nervousness, anxiety: 3 x 1-
2 film tablets daily
Sleeping disorders based on
nervous condition.
Restlessness, nervousness,
anxiety
2 200.2 mg Valeriaenae radix, dry extract ethanolic
70% (V/V), (4-7:1)
45.5 mg Lupuli flos, dry extract methanolic 40%
(V/V), (4-8:1)
(Hova filmtabl.)
1999
film coated
tablet
Adults:
Sleeping disorders: 2 db film tablets half
an hour before going to bed.
Restlessness, nervousness, anxiety: 1-3 x
1 film tablets daily.
Sleeping disorders based on
nervous condition.
Restlessness, nervousness,
anxiety
3 187.5 mg Valerianae rad. dry extr.methanolic
45% , (5-8:1)
42 mg Lupuli strobuli dry extr.methanolic 45%
,(7-10:1) (Béres Redormin filmtabl.)
2003
film coated
tablet
Adults: 2 db film tablets an hour before
going to bed. This dosage can be
enhanced for 3 filmtablets
Children: 6 years or above 1 filmtablet
Elderly : the same as adults
Sleeping disorders based on
nervous condition
TU
No Marketing status
Year
Pharm form Posology
Indications
1 80.00 mg Valerianae radix extr. sicc. (4-6:1)
extractant: aqua purificata
20.00 mg Lupuli flos extr. sicc. (3-6:1)
extractant: aqua purificata
(Cirkulin Valerian with hops mite dragées)
1994
film coated
tablet
Adults and elderly: 2-3 x 1-2 dragées
Reduces nervousness, tensions,
facilitates getting to sleep
2 160.00 mg Valerianae radicis officinalis extr.
aqu..sicc. (4-6:1)
40.00 mg Lupulis flos extr. aqu. sicc. (3-6:1)
2002
film coated
tablet
Adults and elderly: 1-2 x 1 dragées
Reduces nervousness, tensions,
facilitates getting to sleep
(Cirkulin Valerian with hops forte dragées)
EMEA 2009
19/40
Additional information:
Sager Pharma/Gebro Pharma (1996) Hova film coated tablets; 220mg valerian root dry
extract (4-7:1, ethanol 70% v/v) and 65.0 mg hops dry ectract (4-8:1,
methanol 40% v/v).
Finzelberg/Flachsmann
Hova film tablets ; 200.2 mg valerian root dry extract
and 45.5 mg hops dry extract
EMEA 2009
20/40
ICELAND
No combinations of hop and valerian.
ITALY
No combinations of hop and valerian.
LATVIA
No combinations of hop and valerian.
NORWAY
No combinations of hop and valerian.
POLAND
WEU
No Marketing status
Year
Pharm form Posology
Indications
TU
No Marketing status
Year
Pharm form Posology
Indications
1
Hova
- Valerianae radix, extractum siccum (4-7:1)
220mg, extraction solvent – ethanol 70% v/v
Lupuli strobilus, extractum siccum (4-8:1) 65mg,
extraction solvent methanol 40% v/v
1999
Film-coated
tablet
oral use – 1 tablet 1-3 times daily
sleep disorders
psychosomatic stomach spasms
EMEA 2009
21/40
ROMANIA
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 Redormin; MA: 2004
Composition: 250.0mg Valerianae radix
extractum siccum (4-6:1)
Extration solvent:Methanol 45%;Carrier:
maltodextrin 25%
60.0mg
Lupuli flos extractum siccum (5-7:1)
Extraction solvent:Methanol 45%:Carrier:
maltodextrin 30%
Excipiens q.s. ad 570mg
2004
Film-coated
tablets
Adults: 2 tablets one hour before going to
bed. If required, the dose can be increased
to 3 tablets.
Children over 12 years of age: 1 tablet
one hour before going to bed
Elderly: as for adults: 2 tablets
Adjuvant in case of difficulties in
falling asleep and sleeping
through the night as well as
uneasy sleep.
TU
No Marketing status
Year
Pharm form Posology
Indications
SLOVENIA
WEU
No Marketing status
Year
Pharm form Posology
Indications
1 tablet contains 200.2 mg of Valeriana officinalis
L., radix, extractum siccum (5 : 1); extraction
solvent: 70 % (V/V) ethanol and 45.5 mg of
Humulus lupulus L., flos, extractum siccum (5,5 :
1); extraction solvent: 40 % (V/V) methanol
1999
film-coated
tablet
a) Adults and children above 12 years:
2 film-coated tablets half to one hour
before bedtime
b) Adults and children above 12 years:
1 film-coated tablets up to three times a
day
a) Mild insomnia as a
consequence of tenseness,
restlessness
b) mild nervous tension
TU
No Marketing status
Year
Pharm form Posology
Indications
EMEA 2009
22/40
SPAIN
Not combination of hop and valerian.
SWEDEN
WEU
No Marketing status
Year
Pharm form Posology
Indications
TU
No Marketing status
Year
Pharm form Posology
Indications
1
1 ml contains: 460 mg Valeriana officinalis,
root, tincture (1:10) and 460 mg Humulus
lupulus, strobiles, tincture (1:2.2)
100 ml solution corresponds to 24 g fresh
valerian root corresponding to (approx 5 g
dried root) and 23 g fresh hops (approx 5 g
dried herbal substance).
1978
oral drops
Adults and adolescents:
Nervous tension: 40 drops in ½ glass of
water 3-5 times daily.
Insomnia: 75 drops in ½ glass of water.
Not recommended to children
Traditionally used for minor
nervous tension and temporary
insomnia
.
EMEA 2009
23/40
Assessor’s comments
The herbal preparations with marketing authorizations consist of fixed combinations of dry extracts of
valerian root and hop strobiles, prepared with water, methanol/water or ethanol/water. Their
pharmaceutical forms are coated tablets, soft capsules or film-coated tablets. These products are
marketed in Austria, Belgium, Bulgaria, Czech Republic, Finland, Germany, Hungary, Ireland,
Romania, Slovenia and the United Kingdom. In Austria, Czech Republic, Germany, Hungary,
Norway, Poland and Sweden several herbal preparations are traditionally used and consist not only of
fixed combinations of dry extracts, but also of liquid extracts and/or tinctures. A soft extract of a
mixture of both herbal substances is traditionally used as bath additive in Germany.
The dry extracts of valerian root (3-8:1) are prepared with water, methanol/water (methanol 40-51.2%,
v/v) or ethanol/water (ethanol 40-80%, v/v). The dry extracts of hop strobiles (3-14:1) are also
prepared with water, methanol/water (methanol 25-51.25%, v/v) or ethanol/water (ethanol 40-96%,
v/v). These dry extracts are mixed in fixed combinations of valerian root and hop strobile dry extracts
varying between 80 mg – 250 mg valerian root dry extract and 14 mg – 68 mg hop strobile dry extract.
Only the herbal preparations which have been used in the controlled clinical studies of good
methodological quality can be considered as preparations for well-established use. It concerns the
following fixed combinations of dry extracts :
-
250 mg or 500 mg valerian dry extract (5.3:1, methanol 45% m/m) and 60 mg or 120 mg hop dry
extract (6.6:1, methanol 45% m/m)
-
200.2 mg valerian dry extract (5:1, ethanol 70% v/v) and 45.5 mg hop dry extract (5.5:1, methanol
50% v/v)
-
187 mg valerian dry extract (5-8:1, methanol 45% m/m) and 41.9 mg hop dry extract (7-10:1,
methanol 45% m/)
(See also under section II.3.2.2)
The other fixed combinations including those which have obtained a national marketing authorization
should be considered for traditional use, if they have been for more than 30 years on the market in
Europe. Since no liquid preparations have been clinically tested, they should also be considered for
traditional use. Since the clinical studies mainly involve non-organic insomnia, ‘restlessness’ should
not be taken as an indication for herbal preparations intended for well-established use.
EMEA 2009
24/40
II.1.2.
Information on period of medicinal use in the Community regarding
the specified indication
Fixed combinations of dry extracts of valerian root and hop strobiles have obtained a marketing
authorization in Austria, Belgium, Bulgaria, the Czech Republic, Finland, Germany, Hungary, Ireland,
Romania, Slovenia and the United Kingdom, whereas traditional uses of such combinations have been
reported by Austria, the Czech Republic, Germany, Hungary, Norway, Poland and Sweden. In most of
these countries also other combinations are used for the same indications.
Out of 36 fixed combinations not less than 29 have obtained a marketing authorization in Germany
since 1976. Only one fixed combination with marketing authorization is more than 10 years on the
market in Hungary, whereas the preparations for traditional use have only been on the market since
1994. One fixed combination consisting of tinctures of valerian root and hop strobile has been
traditionally used in Sweden since 1978.
Assessor’s comments
Fixed combinations of dry extracts of valerian root and hop strobiles have obtained a marketing
authorization in several countries for the same indication as valerian preparations alone,
viz.
relief of mild nervous tension and sleep disorders, for more than 10 years. Several other fixed
combinations of dry extracts, liquid extracts or soft extracts are traditionally used for more than
30 years for the same indication as valerian preparations alone,
viz.
to support mental
relaxation.
II.2.
NON-CLINICAL DATA
The phytochemical composition, the pharmacology (II.2.1.), the pharmacokinetics (II.2.2.) and the
toxicology (II.2.3.) of both valerian root and hop strobiles and their preparations have amply been
discussed in the assessment reports on valerian root and hop strobiles (EMEA/HMPC/167391/2006
and EMEA/HMPC/513618/2006, respectively).
One pharmacological study has been performed with both a valerian preparation and a fixed valerian-
hops preparation. An
in vitro
radioligand binding assay at A
1
and A
2A
adenosine receptors (ARs) was
conducted with a fixed extract combination of valerian and hop (Ze 91019) to investigate a possible
mechanism for the pharmacological activity of the extracts. Component extracts of valerian and hop
were also individually investigated. The fixed combination as well as the valerian extracts therein
exhibited selective affinity to A
1
ARs (K(i) = 0.15-0.37 mg/ml versus [
3
H]-N
6
-cyclopentenyladenosine
(CPA). The same extracts exhibited partial agonist activity at the A
1
receptor as indicated by a lower
degree of stimulation of [
35
S]-CTPγS binding in membrane preparations of CHO-hA
1
cells as
EMEA 2009
25/40
compared to full A
1
AR agonist N
6
-CPA. In addition valerian extract inhibited c-AMP accumulation
in CHO-hA
1
cell membranes. The partial agonistic activity at A
1
ARs may thus play a role in the sleep
inducing effect of Ze 91019 and the valerian extract therein (Müller et al., 2002).
Assessor’s comments
Orally administered dry extracts of valerian root in the recommended dosage have shown to improve
sleep latency and sleep quality. Although these effects cannot be attributed with certainty to any
known constituents, several mechanisms of action have been identified for several constituents of
valerian root i.e. sesquiterpenes, lignans and flavonoids, including interactions with the GABA-
system, agonism at the A1-adenosine receptor and binding to the 5-HT
1A
receptor (Balduini and
Cattabeni, 1989; Mennini et al., 1993; Yuan et al., 2004; Cavadas et al., 1995 and Ortiz et al., 1999).
Orally administered dry extracts of hops in mice have shown to decrease body temperature, through
activation of melatonin receptors (Grundmann et al., 2006; Butterweck et al., 2007).
Further studies with a combination of valerian and hops dry extracts have shown interactions with the
serotoninergic 5-HT
4e
, 5-HT
6
, 5-HT
7
and melatoninergic ML
1
and ML
2
receptors (Abourashad et al.,
2004; Brattström, 2007).
According to these authors, the efficacy of a valerian root and hops combination in sleep disorders
could scientifically be explained by the adenosine-like action of valerian root and the melatonin-like
effect of hops, which respectively would increase the sleep propensity and the entrainment of the
circadian rythm.
Few experimental data are available on the toxicology of valerian root preparations which as a whole
point to a low toxicity. The safety assessment has been mainly based on the long experience from the
extensive therapeutic use in man, which indicates valerian root preparations to be safe. Adequate data,
however, on genotoxicity are lacking (von Skramlik, 1959; Rücker et al., 1978; Hendriks et al., 1985;
Bos et al., 1998; Romero-Jimenez et al., 2005).
Given the history of tong term use in humans with no adverse effects, also hops is believed to be non-
toxic and safe. The experimental toxicological data on hop preparations are rather limited and
incomplete, but as a whole uses in man are pointing to a low toxicit y (Milligan et al., 2002; Stevens et
al., 2004; Gerhauser et al., 2005). Adequate data on genotoxicity of hop preparations are also lacking
(Göggelman et al., 1986).
EMEA 2009
26/40
II.3.
CLINICAL DATA
II.3.1.
Clinical pharmacology
II.3.1.1.
Pharmacodynamics
Two pharmacological studies have been carried out with a fixed combination of valerian and hop
extracts (Ze 91019) to investigate the pharmacodynamic effects in healthy volunteers.
In a first study the fixed combination of valerian and hops was investigated aiming at a demonstration
of competition between caffeine and this combination.
Electroencephalographic (EEG) recordings were used to describe the action of caffeine on the central
nervous system after oral administration (200 mg) in healthy volunteers. In addition to caffeine, the
volunteers (16 in each group) received either placebo or verum (2 and 6 tablets containing the
valerian/hop extract).
The EEG responses were recorded every 30 min. The verum medication was capable of reducing (2
tablets) or inhibiting (6 tablets) the arousal induced by caffeine. This pharmacological action was
observed 60 minutes after oral administration indicating not only competition between the antagonist
caffeine and the partial agonist i.e. the valerian/hop extract but also bioavailability of the compound(s)
responsible for the agonistic action. The authors concluded that the valerian/hop extract acts via a
central adenosine mechanism, which is possibly the reason for its sleep-inducing and- maintaining
activity (Schellenberg et al., 2004).
In a second investigation the pharmacodynamic effects of different dosages of a fixed combination of
valerian and hop extracts (Ze 91019) on the quantitative topographical EEG (qEEG) in healthy
volunteers were compared to placebo. Two different dosages were applied in two single-blind, cross-
over designed observation trials in 12 healthy volunteers (1st dosage : 500 mg valerian and 120 mg
hops, versus placebo, first clinical trial ; 2nd dosage : 1500 mg valerian and 360 mg hops, versus
placebo, second clinical trial). The qEEG was recorded bipolarly from 17 surface electrodes according
to the 10:20 system and analysed using the Fast Fourier Transformation prior to, 1, 2 and 4 hours after
drug intake in the recording conditions eyes open, eyes closed and under mental demand. The EEG-
spectra were cut into six frequency bands. Both resting conditions (eyes open and eyes closed) were
analysed together. After application of the low dosage qEEG power changes remained more or less
within placebo range following the normal circadian rhythmics, except for a tendentious reduction of
alpha- and beta1-power 4 h after drug intake. The high dosage led to power increases in delta,
decreases in alpha and a weak decrease in beta-power. Under mental performance only weak
differences to placebo were seen which are not discussed here. In the CPT (completion of complicated
EMEA 2009
27/40
additions and substractions) the concentration and performance capability were hardly influenced.
However, a minimal increase of mean answer time and mean OK time (time for correct answers) was
observed 4 hours after intake of 2 dragees and 1 hour after 6 dragees of valerian and hops mixture with
more pronounced changes after the low dosage than the high one.
The authors concluded that the qEEG was able to show slight, but clear visible effects on the CNS
especially after intake of the high dosage of Ze 91019 indicating reproducible pharmacodynamic
responses of the target organ (Vonderheid-Guth et al., 2000).
II.3.1.2.
Pharmacokinetics
No data available.
II.3.2. Clinical efficacy
Besides one dose-finding trial in short-term clinical use of valerian root, which showed a dose-
dependent effect for the tested doses of 1300 mg and 2600 mg of valerian root (Leathwood, 1985),
four randomized double-blind placebo-controlled and/or reference controlled clinical studies have
been carried out with single valerian root preparations in patients suffering from non-organic insomnia
(Vorbach et al., 1996, Dorn, 2000, Ziegler et al., 2002, Coxeter et al., 2003). Two further placebo-
controlled double-blind clinical studies with valerian root preparations were carried out to assess
besides insomnia also nervous tension (Kamm-Kohl et al., 1984, Jacobs et al., 2005). All these studies
led to the conclusion that valerian extracts prepared with ethanol/water belong to the herbal
preparations with well-established medicinal use for the relief of mild nervous tension and sleep
disorders.
Up to now no meaningful clinical studies have been reported to support hops as single preparation for
the treatment of sleep disorders or nervous tension.
Nevertheless, several non-controlled as well as controlled clinical studies, have demonstrated that
combinations of hop strobiles with valerian root are effective for non-organic insomnia.
II.3.2.1.
Non-controlled clinical studies
An open, multicentre post-marketing surveillance study assessed the efficacy and safety of Ze 91019
in 3,447 patients with sleep disorders. With the intake of the drug product the number of patients
indicating an uninterrupted sleep increased from 7.6 to 32.9%. Patients said to be more relaxed and
have a better performance. Efficacy was judged by the physicians as good-very good in 74.9% of
cases, and as acceptable in 16.3%. Only 19 patients reported adverse events, of which 6 were assessed
as possibly related to the study medication, all of them gastrointestinal complaints (Brattström 1996;
Lataster and Brattström 1996).
EMEA 2009
28/40
Benzodiazepine-induced changes in sleep architecture were reported as demonstrated by
polysomnography. The report is anecdotal, with no details given. When withdrawn from
benzodiazepines and switched to a valerian-hop combination (Ze 91019), the patient’s hypnograms
distinctly changed towards normal patterns. Tolerability was very good, with the exception of
occasional gastrointestinal discomfort (no numbers given) (Flesch 1997).
Another open polysomnographic examination was conducted in 30 patients with non-organic sleep
disorders. Patients were tested before and after a 14-day intake of two tablets of Ze 91019 two hours
before bedtime. Test parameters were EEG measurements, respiration/snoring, sleep quality (verbal
rating scale), and a psychometric test for the detection of trouble with focussing and memory. In all
patients a shift towards a normalisation of sleep architecture (REM / non-REM phases) was found.
Sleep stage 1 was reduced, and slow wave sleep increased. Sleep latency 2 (mean time to reach sleep
stage 2) declined significantly within the 2 weeks of treatment, and the total wake time also declined
significantly. Correspondingly, sleep efficiency (ratio of true sleep time to time spent in bed) improved
significantly. The effects on sleep parameters were paralleled with a subjectively ameliorated feeling
of well-being. No adverse effects occurred in this open pilot study (Brattström 1996; Füssel et al.
2000).
Results of a non-controlled multicentre study with 144 patients (88 women, 56 men; age range 11-91
years) suffering from sleep disorders were reported. Patients received Ze 91019 (1 to 2 coated tablets
one hour before bedtime) for 4 weeks. Patients assessed sleep parameters (sleep latency, sleep
duration, frequency of awakening) and well-being before and after treatment on a VAS (visual
analogical scale). In 25.9% of patients the sleep disorder had completely resolved after therapy.
Severity of the sleep disorders had distinctly shifted towards milder forms. A responder rate of 67%
was calculated. Patients with complaints of interrupted sleep reacted best to the treatment (71%),
followed by trouble falling asleep (67%) and sleep disorders of psychological origin (67%). The
improvement of sleep parameters was paralleled by improvements of well-being (e.g. feeling
refreshed) in the same scale. Sleep duration was increased by approximately 1 hour in average. 66.9%
of patients indicated an onset of effects within the first 10 days of treatment. Tolerability was judged
good-very good by 92% of patients. Adverse events were reported by four patients, and explicitly
stated by two: 1x oedema, 1x diarrhoea (Notter et al., 2003).
In a non-controlled, multicentre study, 480 patients (305 women, 175 men; mean age 49.5 years)
suffering from nervous sleep disorders and restlessness were treated for an average of 22 days with a
combination preparation containing 225 mg valerian root extract (DER 6-7:1; 70% ethanol) and 30 mg
dry extract of hop strobile extract (DER 11-14:1; 96% ethanol) per coated tablet, corresponding to
approximately 1500 mg of valerian root respectively 400 mg of hop strobile per tablet. The mean dose
EMEA 2009
29/40
of the combination was 2.6 coated tablets during the day and 1.6 tablets before bedtime in the evening.
The mean total daily dose was 3.3 tablets. Main efficacy parameters evaluated were improvement of
nervous anxiety and associated psycho-vegetative symptoms (sweating, palpitations, nervous tension)
as well as the improvement of sleep disorders. Symptoms were evaluated with a 5-point rating scale (0
= not present to 4 = severe). Therapy with the valerian-hop combination resulted in pronounced
improvement of both, anxiety and sleep disorders. The rating of anxiety related symptoms was
reduced by 50-57%, symptoms related to sleep parameters were reduced by 58-61%. Global efficacy
was assessed as “excellent” or “good” by 24.6% and 57.2% of patients, respectively. No adverse
events were reported throughout the study (Wegener, 2003).
II.3.2.2.
Controlled clinical studies
A placebo-controlled double-blind study was performed in 12 patients (6 men, 6 women) aged 22-27
years, with traffic noise-induced disturbance of sleep. Patients ingested coated tablets with either 60
mg of valerian root extract (Valeriana officinalis, DER 4.5:1 methanol 40% v/v) and 100 mg extract of
hop strobile extract (Humulus lupulus, DER 5:1 methanol 30% v/v), or placebo. Study duration was 6
nights. During the third, fourth and fifth night traffic noise was simulated during the whole night by
playing tape recordings. Six patients received four tablets of verum (corresponding to 240 mg of
valerian extract or 1572 mg of valerian root, and 400 mg of hop extract or 4000 mg of hop strobiles)
prior to the second, 6 patients prior to the third noisy night. The remaining nights, 4 tablets of placebo
were administered. The traffic noise had an influence on sleep architecture (measured by
polysomnography), however, an adaption to the noise could be observed. The results from the two
treatment arms (second respectively third noisy night) were not comparable.
However, the results clearly showed a beneficial influence of the valerian-hop combination on sleep
architecture by countering the stressful effects of noise. Adverse events were not reported. It is
recommended that the initial treatment of severe insomnia by “strong” sleeping pills should be
followed by a period during which “weak” sleeping pills are given before the drug administration
finally is discontinued (Müller-Limmroth and Ehrenstein, 1977).
In one study, Leathwood et al., 1982, compared the valerian-monopreparation with a combination
valerian-hops and placebo in volunteers.
A cross-over trial comparing an aqueous valerian dry extract (400 mg corresponding to 1180 mg of the
drug), placebo and a combination of valerian dry extract (120 mg/tablet) plus hop strobile dry extract
(60 mg) was performed in 166 volunteers.
Drug/extract ratios for the latter preparation are not given. The volunteers took one dose of totally nine
(three/preparation) on non-consecutive nights and documented their sleep quality in a questionnaire
(not validated). Results were analyzed only for those volunteers who completed the trial (n = 128). Of
them 52% (n=67) were good sleepers and 48% (n=61) were considered as poor or irregular sleepers.
EMEA 2009
30/40
On the morning after taking the preparation, time to fall asleep, quality of sleep, natural waking up,
dreaming and tiredness in the morning were recorded by means of a questionnaire. Time to fall asleep
was reduced in 37% of persons taking the valerian root mono-preparation, in 23% under placebo and
in 31% under the combination preparation. The difference between the valerian root mono-preparation
and placebo was statistically significant (p<0.01). While quality of sleep remained virtually unchanged
in habitually good sleepers with all preparations, in habitually poor or irregular sleepers the sleep
quality was enhanced and sleep latency was reduced significantly more often with the valerian
preparation compared to placebo. The combination showed no signfiicant superiority. The quality of
sleep was improved in 43% of persons with the valerian root mono-preparation and 25% with placebo
(p<0.05). No differences in waking up during the night, dreaming and tiredness in the morning were
found between valerian root and placebo. With regard to the combination preparation, a stronger effect
was found for tiredness in the morning, which was statistically significant compared to both placebo
and valerian root mono-preparation. No significant differences were found for the other parameters.
The interpretation of these data is restricted by lacking of a confirmatory analysis. No detailed
demographic data are given, no validated questionnaires were used in this trial. It is not clear from the
publication whether the medications were taken in a randomized order. Nevertheless, the results are
congruent with those of better designed and reported trials.
In a placebo-controlled, double-blind, randomized parallel group study, the effects of Ze 91019 on
sleep architecture were tested in 15 patients with non-organic insomnia. Patients received 2 tablets of
IVEL
®
(250 mg of valerian extract (5:1 ; solvent not known) and 60 mg of hop extract (6:1 ; solvent
not known) per tablet ; n = 8) or placebo (n = 7). Study duration was 4 weeks. Polysomnographic
recordings were obtained in the sleep laboratory at baseline, after 4 weeks of intake of the study
mediation, and after a 2-week wash-out period. The application of the combination significantly
decreased slow-wave-sleep percentages and increased sleep stage II as compared to placebo. This
finding points to GABAergic effects of the herbal combination. Mild side effects occurred with two
patients in the placebo group and four patients in the verum group consisting of gastro-intestinal
complaints and headache. Based on their results, the authors recommend valerian preparations in
patients with mild, non-chronified sleep disorders (Rodenbeck and Hajek, 1998).
The efficacy of a valerian-hop combination (coated tablets containing 200.2 mg of dry extract of
valerian root (DER 5:1, ethanol 70% v/v) and 45.5 mg of dry extract of hop strobiles (DER 5.5:1,
methanol 40% v/v); extraction solvents not indicated) was compared to that of 3 mg bromazepam in a
two-week reference-controlled, double-blind, randomized clinical parallel group trial with double-
dummy technique. 46 patients (37 women, 9 men; mean age 50.3 years) suffering from non-
psychiatric sleep disorders were tested for sleep quality, fitness and quality of life by psychometric
tests, psychopathologic scales and sleep-questionnaires. All parameters improved in both treatment
EMEA 2009
31/40
groups to a similar extent. During treatment with the herbal combination the percentage of patients
subjectively feeling “bad” or “moderate” decreased by 62.6% (from 82.6% to 20%), as compared to a
reduction of 32.7% (from 56.5% to 23.8%) in patients treated with bromazepam. Seven adverse events
were noted, two of which (one case of gastrointestinal complaints in both treatment arms) were
considered to have been caused by the medication. (Schmitz and Jäckel, 1998).
In 2005, Morin et al. evaluated the efficacy and safety of a valerian-hops combination and
diphenhydramine for the treatment of mild insomnia. The multicentre, randomized, placebo-
controlled, parallel-group study was conducted in 9 sleep disorders centres throughout the US. A total
of 184 adults (110 women, 74 men, mean age of 44.3 year) with mild insomnia were treated with two
nightly tablets of standardized extracts of valerian (187 mg native extract : 5-8:1, methanol 45% m/m)
and hops (41.9 mg native extract : 7-10:1, methanol 45% m/m) combination for 28 days (n = 59) and a
placebo for 28 days (n = 65) or 2 tablets of diphenhydramine (25 mg) for 14 days followed by placebo
for 14 days (n = 60). Sleep parameters measured by daily diaries and polysomnography, clinical
outcome ratings from patients and physicians, and quality of life measures were the outcome
measures. Modest improvements of subjective sleep parameters were obtained with both the valerian-
hops combination and diphenhydramine, but few comparisons with placebo reached statistical
significance. Valerian-hops produced sligtly greater, though nonsignificant, reductions of sleep latency
relative to placebo and diphenhydramine at the end of 14 days of treatment and greater reductions than
placebo at the end of 28 days of treatments. Diphenhydramine produced significantly greater increases
in sleep efficiency and a trend for increased total sleep time relative to placebo during the first 14 days
of treatments. There were no significant group differences on any other sleep continuity variables
measured by polysomnography.
In addition, there was no alteration of sleep stages 3 and 4 and rapid eye movement sleep with any of
the treatments. Patients in the valerian-hops and diphenhydramine groups rated their insomnia severity
lower relative to placebo at the end of 14 days of treatment. Quality life (physical component) was
significantly more improved in the valerian-hops group relative to the placebo group at the end of 28
days. There were no significant residual effects and no serious adverse events with either valerian-
hops or diphenhydramine and no reboud insomnia following their discontinuation.
The authors concluded that their findings show a modest hypnotic effect for a valerian-hops
combination and diphenhydramine relative to placebo. Sleep improvements with a valerian-hops
combination are associated with improved quality of life. Both treatments appeared safe and did not
produce rebound insomnia upon discontinuation during this study.
Overall, these findings indicate that a valerian-hops combination and diphenhydramine might be
useful adjuncts in the treatment of mild insomnia (Morin et al., 2005).
EMEA 2009
32/40
Recently, another randomized blind three-armed clinical study was carried out investigating the fixed
extract combination Ze 91019 (valerian and hops) in comparison with a comparable single valerian
extract (Ze 911) and a placebo in 30 patients (i.e. 10 patients in each study) suffering from non-
organic insomnia (ICD10, F51.0-51.2).
Objective sleep parameters were registered by means of transportable home recorder system (QUISI).
The primary outcome was the reduction in sleep latency (SL2) which had to be prolonged at baseline
(≥ 30 min) as an inclusion criteria. The treatment period lasted for 4 weeks (one medication daily)
with either placebo, single valerian extract (Ze 911) or the fixed valerian hops extracts combination
(Ze 91019). The amount of the single valerian extract was identical to that amount contained in the
fixed extract combination i.e. 500 mg valerian dry extract. In the extract combination 120 mg hops dry
extract was added (Ze 91019). Both the extracts were prepared with 45% methanol m/m with a DER
of 5.3:1 (valerian) and 6.6:1 (hops), respectively.
The fixed extract combination was significantly superior to the placebo in reducing the sleep latency,
whilst the single valerian extract even if it showed some improvement regarding sleep latency, failed
to reach significant superiority compared with the placebo. No adverse events were reported for any of
the patients in the different groups which underlined the safety (Koetter et al., 2007).
EMEA 2009
33/40
Table 1
Con
trolled clinical studies with valerian-hop extracts combinations
Authors
Indications
Study design
Formulation
(single dosage)
Dose/Duration
Test criteria/
Efficacy
Safety
Comments
Müller-
Limroth
and
Ehrenstein,
1977
Investigation
of sleep
quality in
sleep
disturbed
subjects
Double-blind
Placebo-
controlled
n=12
Coated tablets of 60 mg
valerian dry extract
(4.5:1, methanol 40%
v/v) and 100 mg hop
dry extract (5:1,
methanol 30% v/v)
n=12
Study duration:
6 nights
Traffic noise during
nights 3, 4 and 5
4 Tablets of verum to 6
patients prior to night 2
and to 6 patients prior
to night 3
Remaining nights:
4 tablets of placebo
Polysomnography
----------------------------
Reduction of the noise
induced disturbance of
sleep stage pattern
Slow-wave-sleep and
stage REM increased
No adverse
events
Number of
volunteers is
too restricted
to draw
conclusions
Leathwood et
al., 1982
Investigation
of sleep
quality of
volunteers
Cross-over trial
comparing
aqueous valerian
dry extract,
placebo and a
combinaton of
valerian and hop
extracts n=128
volunteers
(67 good and 61
poor sleepers)
400 mg of valerian dry
extract (2.8:1, water)
Placebo
Hova
®
capsules
(Zyma):
60 mg valerian dry
extract and 30 mg hop
dry extract
Preparation unknown
400 mg of valerian
aqueous dry extract
2 capsules of 200 mg
Hova
®
One dose of 9
(3 per preparation) on
non- consecutive nights
Questionnaire to fill in
by the
volunteers
---
Significant differences
between valerian
extract and placebo,
but not between
combination and
placebo
Stronger effect
for tiredness in
the morning for
the combination
compared to
placebo and
monopreparation
No
confirmatory
analysis
No validated
Question-
naire
Are
medications
taken in a
randomized
order?
EMEA 2009
34/40
Table 1
Controlled
clinical studies with valerian-hop extracts combinations (continued)
Authors
Indications
Study design
Formulation
(single dosage)
Dose/Duration
Test criteria/
Efficacy
Safety
Comments
Rodenbeck
&
Hajek, 1998
Non-organic
insomnia
(DSM-III-R)
(ApA, 1987)
Randomized
Double-blind
Placebo-controlled
n=8 (verum)
n=7 (placebo)
IVEL
®
-tablets (Knoll)
250 mg valerian dry
extract
(5:1) solvent?
60 mg hop dry extract
(6:1) solvent?
2 tablets/day
30 min before bedtime
4 weeks
(57 days of therapy)
Polysomnography ;
Subjective feelings
----------------------------
------
Decrease of slow-
wave-sleep
Increase of sleep stage
II in the verum group
Placebo n:2
Verum n=4
Gastro-intestinal
complaints and
headache
Extraction
solvent is not
given:
probably
identifical to
Ze 91019 and
consequently
methanol
45% m/m
Number of
patients is
limited;
statis-tical
significance
is doubtful
Schmitz and
Jäckel, 1998
Sleep
disorders
(DSM-IV)
Randomized
Double-blind
Reference-
controlled
Lexotanil
®
(3 mg
bromazepam)
n=46
Hova
®
film tablets
200.2 mg valerian dry
extract (5:1, ethanol
70% v/v)
45.5 mg hop dry
extract
(5.5:1, methanol 40%
v/v)
2 weeks therapy
1 week cessation of
therapy
Psychometric tests
Psychopathological
scales; Sleep
questionnaires
----------------------------
Equivalence of both
therapies according to
sleep quality, fitness
and quality of life
n=1 with
stomach
complaints in
both groups
Extraction
solvent is not
mentioned in
the
publication,
but
corresponds
to Hova
®
2 film tablets (verum)
and 1 capsule
(reference) 30 min
before bedtime/day
No placebo-
controlled
study, but of
good
methodologic
al quality
EMEA 2009
35/40
Table 1
Controlled
clinical studies with valerian-hop extracts combinations (continued)
Authors
Indications
Study design
Formulation
(single dosage)
Dose/Duration
Test criteria/
Efficacy
Safety
Comments
Morin et
al., 2005
Mild
insomnia
Randomized
Double-blind
Placebo-controlled
Multicentre (n=9)
Reference-
controlled
Diphenhydramine:
25 mg/tablet
Tablets of 187 mg of
valerian dry extract
(5-8:1, methanol 45%
m/m) and 41.9 mg of
hop dry extract (7-10:1,
methanol 45% m/m)
1.
2 nightly tablets of
combination for 28
days (n=59)
2.
placebo for 28 days
(n=65)
3.
2 tablets of
diphenhydramine for
14 days followed by
placebo for 14 days
(n=60)
Sleep parameters
measured by daily
diairies and poly-
somnography,
Clinical outcome
ratings for patients
and physicians and
quality of life
measures
No serious
adverse
events
Study of good
methodological
quality
Modest hypnotic
effect for valerian-
hops combination and
diphenhydramine
relative to placebo.
Sleep improvements
with valerian-hops
combination are
associated with
improved quality of
life.
Both treatments
appear safe and did
not produce rebound
insomnia after
discontinuation
during this study.
Both preparations are
useful adjuncts in the
treatment of mild
insomnia
EMEA 2009
36/40
Table 1
Controlled
clinical studies with valerian-hop extracts combinations (continued)
Authors
Indications
Study design
Formulation
(single dosage)
Dose/Duration
Test criteria/
Efficacy
Safety
Comments
Koetter et
al., 2007
Non-organic
sleep
disorders
(ICD 10,
F51.0-51.2)
Randomized
Double-blind
Placebo-controlled
Fixed combination
and valerian mono-
extract versus
placebo
Fixed extract
combination :
Ze 91019 :
500 mg valerian dry
extract (5.3:1, methanol
45% m/m) and 120 mg
hop dry extract (6.6:1,
methanol 45% m/m)
4 weeks : one dosage/day Objective sleep
parameters
determined by means
of a transportable
home recorder system
(QUISI) Clinical
global impression
scale
--------------------------
Reduction of sleep
latency (≥ 30 min) in
patients suffering
from primary
insomnia with
combination. Single
extract was not
superior than placebo
No secondary
events
Study of good
methodological
quality
n=30 (three arms :
n=10 per arm)
Pure valerian extract Ze
911:
500 mg valerian dry
extract (5.3:1, methanol
45% m/m)
EMEA 2009
37/40
Assessor’s comments
In four non-controlled clinical studies and two randomized placebo-controlled double-blind clinical
studies a fixed dry extract combination (Ze 91019) of valerian root and hop strobiles was used to treat
patients suffering from non-organic disorders. Both extracts were prepared with 45% methanol m/m
with a dry extract ratio of 5.3:1 (valerian) and 6.6:1 (hops), respectively. In only one of these
controlled clinical studies (Koetter et al., 2007) the combination product was significantly superior to
the placebo. In the other controlled clinical study (Rodenbeck and Hajek, 1998) the number of patients
being 15 was too limited to obtain a statistically significant conclusion. Tolerability was very good
with the exception of occasional gastro-intestinal discomfort in a small number of patients in four of
the abovementioned studies.
In one randomized, reference-controlled (bromazepam as reference) double-blind clinical study by
Schmitz and Jäckel (1998) and one randomized, placebo- and reference-controlled (diphenhydramine
as reference) double-blind clinical study conducted by Morin et al. (2005) modest hypnotic effects for
the fixed valerian-hops combination products were obtained. Equivalence of both reference and
combination products according to sleep quality, fitness and quality of life were found. Both clinical
studies were of good methodological quality. The composition of the combination products was
slightly different from that of Ze 91019
viz.
valerian dry extract (5.8:1) prepared with ethanol 70% v/v
and methanol 45% m/m, respectively and hop dry extract (5.5:1) and (7.10:1) prepared with methanol
40% v/v and methanol 45% m/m, respectively.
In conclusion, preclinical and clinical evidence are sufficient to support a well-established use of
several fixed combinations of valerian root dry extract and hops dry extract to treat patients
suffering from non-organic sleep disorders.
These fixed preparations should be limited to the ones used in the successful controlled clinical
studies
viz
. fixed combinations of 250 mg or 500 mg valerian dry extract (5.3:1, methanol 45%
m/m) and 60 mg or 120 mg hop dry extract (6.6:1 methanol 45% m/m) (Ze 91019), 200.2 mg
valerian dry extract (5:1, ethanol 70% v/v) and 45.5 mg hop dry extract (5.5:1, methanol 40%
v/v) (Hova
®
) and 187 mg valerian dry extract (5-8:1, methanol 45% m/m) and 41.9 mg hop dry
extract (7-10:1, methanol 45% m/m).
EMEA 2009
38/40
II.4. SAFETY
II.4.1. Toxicity
The toxicity of both valerian root and hop strobiles and their preparations have been discussed in the
corresponding assessment reports (EMEA/HMPC/167391/2006 and EMEA/HMPC/513618/2006,
respectively) of the single ingredients.
II.4.2. Side effects
Gastrointestinal symptoms e.g. nausea, abdominal cramps and headache have been reported during the
clinical studies in a small number of patients.
Allergic reactions, which are sometimes seen when handling hop cones or hop oil are not likely to
occur when using hop extract, since allergens are supposed to be removed (Estrada et al., 2002)
.
Although, it is not known whether the dry extracts of hops contain oestrogens such as 8-
prenylnaringenin, it might be supposed that if such substances are present, the amounts must be very
small, since no special methods have been used to enrich the extracts in prenylated flavonones.
II.4.3. Contra-indications, warnings
Patients with known hypersensitivity to the active substances should not use valerian root/hop strobile
preparations.
II.4.4. Interactions
Only limited data on pharmacological interactions of valerian and hop extracts with other medicinal
products are available. Clinical relevant interactions with drugs, dietary supplements and other herbs,
however, are missing.
II.4.5.
Overdoses
Not known.
EMEA 2009
39/40
Assessor’s overall conclusion
The sedative effect of valerian and hop preparations has long been recognised empirically.
Since
more than 10 years fixed combinations of dry extracts of valerian root and hop strobiles have
been used for the treatment of insomnia and recently not only pharmacological investigations,
but also clinical studies have justified this use. The efficacy of such a combination in sleep
disorders can scientifically be explained by the adenosine-like action of valerian root and the
melatonin-like effect of hops, which respectively would increase the sleep propensity and the
entrainment of the circadian rhythm. The preclinical and clinical studies have also shown that
combination products of hops and valerian root dry extracts are well-tolerated and except for
some gastrointestinal discomforts in a small number of patients are devoid of side effects.
Consequently, well-defined fixed combinations of dry extracts of valerian root and hop strobiles
can be accepted as well-established herbal medicinal products for the treatment of sleep
disorders.
Since several other fixed combinations of valerian root and hop strobiles have obtained a
marketing authorisation for more than 30 years for the same indications as single preparations
of hops or valerian, these preparations can also be accepted as traditional herbal medicinal
products for relief of mild symptoms of mental stress and to aid sleep.
Also a fixed combination of liquid extracts and one consisting of tinctures of valerian root and
hop strobiles can be accepted as traditional herbal medicinal products, taking into account the
marketing authorisation of more than 30 years.
EMEA 2009
40/40
Source: European Medicines Agency
- Please bookmark this page (add it to your favorites).
- If you wish to link to this page, you can do so by referring to the URL address below this line.
https://theodora.com/drugs/eu/valerianae_radix_lupuli_flos_herbal.html
Copyright © 1995-2021 ITA all rights reserved.